Use of Surveillance for Hepatocellular Carcinoma Among Patients With Cirrhosis in the United States

被引:317
作者
Davila, Jessica A. [1 ]
Morgan, Robert O. [1 ]
Richardson, Peter A. [1 ]
Du, Xianglin L. [3 ]
McGlynn, Katherine A. [4 ]
El-Serag, Hashem B. [1 ,2 ]
机构
[1] Houston VA Med Ctr, Houston Ctr Qual Care & Utilizat Studies, Sect Hlth Serv Res, Houston, TX USA
[2] Houston VA Med Ctr, Houston Ctr Qual Care & Utilizat Studies, Gastroenterol Sect, Houston, TX USA
[3] Univ Texas Houston, Sch Publ Hlth, Dept Epidemiol, Houston, TX USA
[4] NCI, Div Canc Epidemiol & Genet, US Dept HHS, Bethesda, MD 20892 USA
关键词
HEPATITIS-C; INCREASING INCIDENCE; VIRAL-HEPATITIS; CANCER; MANAGEMENT; INFECTION; SURVIVAL; VETERANS; IMPROVE; STAGE;
D O I
10.1002/hep.23615
中图分类号
R57 [消化系及腹部疾病];
学科分类号
摘要
Surveillance for hepatocellular carcinoma (HCC) in patients with cirrhosis is recommended but may not be performed. The extent and determinants of HCC surveillance are unknown. We conducted a population-based United States cohort study of patients over 65 years of age to examine use and determinants of prediagnosis surveillance in patients with HCC who were previously diagnosed with cirrhosis. Patients diagnosed with HCC during 1994-2002 were identified from the linked Surveillance, Epidemiology, and End-Results registry Medicare databases. We identified alpha-fetoprotein (AFP) and ultrasound tests performed for HCC surveillance, and examined factors associated with surveillance. We identified 1,873 HCC patients with a prior diagnosis of cirrhosis. In the 3 years before HCC, 17% received regular surveillance and 38% received inconsistent surveillance. In a subset of 541 patients in whom cirrhosis was recorded for 3 or more years prior to HCC, only 29% received routine surveillance and 33% received inconsistent surveillance. Among all patients who received regular surveillance, approximately 52% received both AFP and ultrasound, 46% received AFP only, and 2% received ultrasound only. Patients receiving regular surveillance were more likely to have lived in urban areas and had higher incomes than those who did not receive surveillance. Before diagnosis, approximately 48% of patients were seen by a gastroenterologist/hepatologist or by a physician with an academic affiliation; they were approximately 4.5-fold and 2.8-fold, respectively, more likely to receive regular surveillance than those seen by a primary care physician only. Geographic variation in surveillance was observed and explained by patient and physician factors. Conclusion: Less than 20% of patients with cirrhosis who developed HCC received regular surveillance. Gastroenterologists/hepatologists or physicians with an academic affiliation are more likely to perform surveillance. (HEPATOLOGY: 2010;52:132-141)
引用
收藏
页码:132 / 141
页数:10
相关论文
共 38 条
[1]   Management of hepatoceullular carcinoma [J].
Bruix, J ;
Sherman, M .
HEPATOLOGY, 2005, 42 (05) :1208-1236
[2]   Clinical management of hepatocellular carcinoma.: Conclusions of the Barcelona-2000 EASL Conference [J].
Bruix, J ;
Sherman, M ;
Llovet, JM ;
Beaugrand, M ;
Lencioni, R ;
Burroughs, AK ;
Christensen, E ;
Pagliaro, L ;
Colombo, M ;
Rodés, J .
JOURNAL OF HEPATOLOGY, 2001, 35 (03) :421-430
[3]   Screening for hepatocellular carcinoma in patients with advanced cirrhosis [J].
Chalasani, N ;
Horlander, JC ;
Said, A ;
Hoen, H ;
Kopecky, KK ;
Stockberger, SM ;
Manam, R ;
Kwo, PY ;
Lumeng, L .
AMERICAN JOURNAL OF GASTROENTEROLOGY, 1999, 94 (10) :2988-2993
[4]   Screening for hepatocellular carcinoma [J].
Colombo, M .
DIGESTION, 1998, 59 :70-71
[5]   Hepatitis C infection and the increasing incidence of hepatocellular carcinoma: A population-based study [J].
Davila, JA ;
Morgan, RO ;
Shaib, Y ;
McGlynn, KA ;
El-Serag, HB .
GASTROENTEROLOGY, 2004, 127 (05) :1372-1380
[6]   Utilization of screening for hepatocellular carcinoma in the United States [J].
Davila, Jessica A. ;
Weston, Allan ;
Smalley, Walter ;
El-Serag, Hashem B. .
JOURNAL OF CLINICAL GASTROENTEROLOGY, 2007, 41 (08) :777-782
[7]   The continuing increase in the incidence of hepatocellular carcinoma in the United States: An update [J].
El-Serag, H ;
Davila, JA ;
Petersen, NJ ;
McGlynn, KA .
ANNALS OF INTERNAL MEDICINE, 2003, 139 (10) :817-823
[8]   Risk factors for the rising rates of primary liver cancer in the United States [J].
El-Serag, HB ;
Mason, AC .
ARCHIVES OF INTERNAL MEDICINE, 2000, 160 (21) :3227-3230
[9]   Treatment and outcomes of treating of hepatocellular carcinoma among Medicare recipients in the United States: A population-based study [J].
El-Serag, HB ;
Siegel, AB ;
Davila, JA ;
Shaib, YH ;
Cayton-Woody, M ;
McBride, R ;
McGlynn, KA .
JOURNAL OF HEPATOLOGY, 2006, 44 (01) :158-166
[10]   Is female sex a significant favorable prognostic factor in hepatocellular carcinoma? [J].
Farinati, Fabio ;
Sergio, Adriana ;
Giacomin, Anna ;
Di Nolfo, Maria Anna ;
Del Poggio, Paolo ;
Benvegnu, Luisa ;
Rapaccini, Gianludovico ;
Zoli, Marco ;
Borzio, Franco ;
Giannini, Edoardo G. ;
Caturelli, Eugenio ;
Trevisani, Franco .
EUROPEAN JOURNAL OF GASTROENTEROLOGY & HEPATOLOGY, 2009, 21 (10) :1212-1218